Dynamics of HBV model with intermittent antiviral therapy

This paper studies the dynamics of the Hepatitis B virus (HBV) model with intermittent antiviral therapy. We first propose a mathematical model of HBV and then analyze its qualitative and dynamical properties with a new treatment therapy. Combining with the clinical data and theoretical analysis, we show that the intermittent antiviral therapy regimen is one of optimal strategies to treat this kind of complex disease. There are two mainly advantages on this therapy. Firstly, it can delay the drug resistance. Secondly, it can reduce the duration of treatment time comparing with the long term continuous therapy, thereby reducing the adverse side effect. Our results clear provides a new way to treat the HBV disease.

[1]  Matthew Kowgier,et al.  Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. , 2010, Gastroenterology.

[2]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Ching-Lung Lai,et al.  Long-term safety of lamivudine treatment in patients with chronic hepatitis B. , 2003, Gastroenterology.

[4]  C. Gibbs,et al.  Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy , 1999, Hepatology.

[5]  A. Perelson.  Modelling viral and immune system dynamics , 2002, Nature Reviews Immunology.

[6]  Gouhei Tanaka,et al.  A Mathematical Model of Intermittent Androgen Suppression for Prostate Cancer , 2008, J. Nonlinear Sci..

[7]  F. Zoulim,et al.  Hepatitis B Virus Drug Resistance and Combination Therapy , 2007 .

[8]  Lequan Min,et al.  Mathematical Analysis of a Basic Virus Infection Model With Application to HBV Infection , 2008 .

[9]  Pietro Andreone,et al.  Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.

[10]  Gouhei Tanaka,et al.  MATHEMATICAL ENGINEERING TECHNICAL REPORTS A Mathematical Model of Intermittent Androgen Suppression Remedy for Prostate Cancer , 2006 .

[11]  Hideyuki Suzuki,et al.  Theory of hybrid dynamical systems and its applications to biological and medical systems , 2010, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[12]  P. Cochat,et al.  Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[13]  J. Watmough,et al.  Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. , 2002, Mathematical biosciences.

[14]  F. Zoulim,et al.  A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine , 2006, Journal of viral hepatitis.

[15]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[16]  A. Lok,et al.  Navigating the maze of hepatitis B treatments. , 2007, Gastroenterology.

[17]  Gouhei Tanaka,et al.  Bifurcation analysis on a hybrid systems model of intermittent hormonal therapy for prostate cancer , 2008 .

[18]  M A Nowak,et al.  Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Kazuyuki Aihara,et al.  Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. , 2010, Journal of theoretical biology.